pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
BRISTOL MYERS SQUIBB CO ($BMY) · news · pharmadog
← back to BRISTOL MYERS SQUIBB CO
News mentioning $BMY
154
stories
21d
Chutes & Ladders—Legend CEO departs without successor in place
fiercebiotech
21d
J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B
biopharma dive
21d
BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delays
biospace
21d
Takeda, Regeneron, Sanofi and Bristol Myers trim pipelines
endpoints
22d
BMS CEO Boerner doesn’t ‘feel any compulsion to chase deals’ despite lack of M&A this year
fiercebiotech
22d
Bristol Myers delays Cobenfy Alzheimer’s psychosis readout again amid another quarterly beat
fiercebiotech
22d
Attovia, Braveheart and Vogenx seek more than $500M across trio of IPOs
fiercebiotech
22d
Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the store
biospace
22d
J&J pays Sail $785M, charting course to possible in vivo CAR-T buyout
fiercebiotech
22d
MapLight CEO on what investors missed in the biotech’s schizophrenia data
biopharma dive
23d
Merck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combination
fiercebiotech
24d
FDA says Replimune’s melanoma data package is ‘not interpretable,’ setting up tough adcomm
biospace
24d
MapLight dives despite positive data for schizophrenia drug
biopharma dive
24d
MapLight’s schizophrenia pill remains in Cobenfy’s shadow after mixed Phase 2 readout
biospace
25d
InnoCare’s oral TYK2 inhibitor clears phase 3 psoriasis test
fiercebiotech
25d
Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdle
biospace
25d
Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
biospace
27d
Anthropic’s life science plans; Novartis CEO on China deals; and more
endpoints
28d
Summit has less than a year of cash runway left as PD-1/VEGF verdict nears
biospace
29d
Scancell to go public after winning reverse merger bid for troubled Neuphoria
fiercebiotech
29d
Biopharma layoffs must double in H2 for 2026 to match 2025 cuts
biospace
29d
Summit and Akeso sharpen case for ivonescimab with new Western data
biospace
Jul 22, 26
Repligen strikes $1.5B BioLife buyout to bag cell therapy product pharmas rely on
biospace
Jul 22, 26
AI data becomes sticking point in biopharma dealmaking
biospace
Jul 21, 26
Dimension restocks with $800M to capitalize on AI’s ‘rapid ascent’
biopharma dive
Jul 21, 26
Is there an exodus underway at Epic?
stat
Jul 21, 26
Indian generics maker Lupin seeds US spinout Kaveri with cash, clinical-phase cancer assets
fiercebiotech
Jul 20, 26
FDA still focused on lettuce supplier as source of parasite, despite faulty test result
stat
Jul 20, 26
STAT+: Pharmalittle: We’re reading about a telehealth firm and patient safety, PBMs overcharging, and more
stat
Jul 20, 26
Bristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide maker
biopharma dive
← prev
page 3 of 6
next →
